Pharmaceuticals News and Research

RSS

Biodegradable and bioresorbable polymers workshop hosted by Lucideon

Lucideon, the international materials technology company, in conjunction with the University of Cambridge, Granta Design, NC State University and the University of North Carolina, is hosting a 2-day ‘Science for Industry’ workshop on Biodegradable and Bioresorbable Polymers (BBPs).

From Lucideon 10 Sep 2015

Rice lab invents technique to characterize nanoscale spaces in porous materials

Rice University scientists led a project to "see" and measure the space in porous materials, even if that space is too small or fragile for traditional microscopes.

10 Sep 2015

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today presented updated clinical data from its Phase I/II study of lead product candidate VAL-083 (dianhydrogalactitol), in patients with refractory glioblastoma multiforme (GBM), at GBM2015: 2nd International Symposium on Clinical and Basic Investigation in Glioblastoma in Toledo, Spain.

10 Sep 2015

CureVac, IAVI team up to advance development, testing of AIDS vaccines

The non-profit International AIDS Vaccine Initiative (IAVI) and biopharmaceutical company CureVac are partnering to accelerate the development of AIDS vaccines, utilizing novel immunogens developed by IAVI and partners, delivered via CureVac's novel messenger RNA (mRNA) technology.

10 Sep 2015

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.

10 Sep 2015

Scientists develop a way to stop pharmaceuticals from contaminating drinking water

In recent years, researchers have realized that many products, including pharmaceuticals, have ended up where they're not supposed to be -- in our drinking water. But now scientists have developed a way to make drugs that break down into harmless compounds before they contaminate our taps.

10 Sep 2015

CRISPR tool streamlines gene editing

Within the past few years, a new technology has made altering genes in plants and animals much easier than before. The tool, called CRISPR/Cas9 or just CRISPR, has spurred a flurry of research that could one day lead to hardier crops and livestock, as well as innovative biomedicines. But along with potential benefits, it raises red flags, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.

10 Sep 2015

Research opens up potential new pathways to vaccine development against HA-MRSA

New research led by NYU Langone Medical Center has uncovered why a particular strain of Staphylococcus aureus -- known as HA-MRSA -- becomes more deadly than other variations. These new findings open up possible new pathways to vaccine development against this bacterium, which the Centers for Disease Control and Preventions says accounts for over 10,000 deaths annually, mostly among hospital patients.

10 Sep 2015

UI scientists discover protein that causes muscle weakness and loss during aging

As we grow older, we lose strength and muscle mass. However, the cause of age-related muscle weakness and atrophy has remained a mystery.

9 Sep 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

9 Sep 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

UCSF researchers lead $10 million research project on pediatric cancer

Researchers at UC San Francisco are leading a five-year, $10 million research project dedicated to pediatric cancer, funded by the first grant of its kind to focus on a molecular pathway that underlies many cancers rather than on a cancer in a particular organ or tissue in the body.

9 Sep 2015

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research.

9 Sep 2015

Children's Cancer Institute awarded NCI grant to fast-track new drugs into clinical trials for childhood cancer

Children's Cancer Institute welcomes its inclusion, by the US National Cancer Institute (NCI), in a systematic program of drug evaluation in childhood cancer.

9 Sep 2015

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

Researchers at Southern Methodist University, Dallas, have discovered three new drug-like compounds that could ultimately offer better odds of survival to prostate cancer patients.

9 Sep 2015

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health in Basel, Switzerland, the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed from the earliest drug discovery stage to combat human African trypanosomiasis, or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly.

9 Sep 2015

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).

8 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

Johnson & Johnson wins Healthiest Company and Healthiest Workforce awards

Johnson & Johnson has been named Britain’s Healthiest Company and recognised as having Britain’s Healthiest Workforce which following the UK’s largest wellness survey, whose findings were validated by a research team at the University of Cambridge.

8 Sep 2015

Pharmaceuticals News and Research

Biodegradable and bioresorbable polymers workshop hosted by Lucideon

Rice lab invents technique to characterize nanoscale spaces in porous materials

DelMar presents updated VAL-083 Phase I/II trial data at GBM2015 meeting

CureVac, IAVI team up to advance development, testing of AIDS vaccines

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

CureVac announces official launch of U.S. operations in Cambridge, MA

Scientists develop a way to stop pharmaceuticals from contaminating drinking water

CRISPR tool streamlines gene editing

Research opens up potential new pathways to vaccine development against HA-MRSA

UI scientists discover protein that causes muscle weakness and loss during aging

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

UCSF researchers lead $10 million research project on pediatric cancer

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

Children's Cancer Institute awarded NCI grant to fast-track new drugs into clinical trials for childhood cancer

Three drug-like compounds may offer better odds of survival to patients with prostate cancer, find SMU researchers

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Johnson & Johnson wins Healthiest Company and Healthiest Workforce awards

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring